What Young Statisticians and Likely Others Expect from Their Management
In this episode, Evanthia, Arina, and I discuss the importance of trust and exposure in career development as well as the expectations of young statisticians.
Innovation
Do You Waste Your and Your Teams Time Without Knowing It? 3 Case Studies and One Reason
In this episode, I discuss three case studies and one overarching reason why it’s crucial to focus on high-impact tasks to maximize the time and effectiveness of medical affairs teams.
Behind the scenes of The Effective Statistician
Today, I have the pleasure of sitting down with Reine Escalona and Kacey Tunac, the podcast production and management team called VVS, who work alongside this successful podcast – The Effective Statistician.
Driving Statistical Innovation – Barriers And Strategies Part 2
In this part 2, Mouna, Kaspar, and I share our insights on the strategies for innovation in statistics for drug development.
Driving Statistical Innovation – Barriers And Strategies Part 1
Statistical innovation is vital in the pharmaceutical industry as it drives evidence-based decisions and brings value to patients. However, it requires a delicate balance between invention and commercialization to achieve success.
Your compound through the eyes of the competition
I discuss an experience with helping a company with their need to communicate data effectively in order to differentiate their compound from the standard of care.
Beyond Regulatory and HTA Success: Reaching Physicians and Patients
In this episode, I discuss how you can have an impact on physicians and patients beyond regulatory and HTA approval.
One-armed observational studies: fake science?
In this episode, we will discuss one-armed observational studies and why they are, in most cases, not a good idea. We will also touch on the early days of my career as a statistician and how I initially approached one-armed observational studies.
RCT Duplicate
In this episode, we discussed RCT Duplicate’s goals and recommendations for real-world evidence researchers based on findings from the initiative.
Single arm studies
Anja Schiel – the most recognised regulatory statistician in Europe – and I discuss the potential drawbacks of running single arm studies, as well as ways to balance scientific rigour with feasibility.
